Orthodontic pain that is induced by tooth movement is an important sequela of orthodontic treatment and has a significant effect on patient quality of life.Studies have shown that the high expression of transient receptor potential vanilloid 1 (TRPV1) in trigeminal ganglions plays a vital role in the transmission and modulation of orofacial pain.However,little is known about the role of TRPV1 in orthodontic pain.in this study,male Sprague-Dawley rats were randomly assigned to six groups to study the role of TRPV1 in the modulation of tooth-movement pain.The expression levels of TRPV1 mRNA and protein were determined by real-time PCR and western blot,respectively.Moreover,pain levels were assessed using the rat grimace scale (RGS).The role of TRPV1 in modulating tooth-movement pain was examined by injecting a TRPV1 antagonist into the trigeminal ganglia of rats.A lentivirus containing a TRPV1 shRNA sequence was constructed and transduced into the rats' trigeminal ganglia.The results showed that the expression levels of TRPV1 protein and mRNA were elevated following tooth-movement pain.Pain levels increased rapidly on the 1st day,peaked on the 3rd day and returned to baseline on the 14th day.The TRPV1 antagonist significantly reduced tooth-movement pain.The lentivirus containing a TRPV1 shRNA sequence was able to inhibit the expression of TRPV1 and relieved tooth-movement pain.In conclusion,TRPV1-based gene therapy may be a treatment strategy for the relief of orthodontic pain.

Orthodontic pain that is induced by tooth movement is an important sequela of orthodontic treatment and has a significant effect on patient quality of life. Studies have shown that the high expression of transient receptor potential vanilloid 1 (TRPV1) in trigeminal ganglions plays a vital role in the transmission and modulation of orofacial pain. However, little is known about the role of TRPV1 in orthodontic pain. In this study, male Sprague-Dawley rats were randomly assigned to six groups to study the role of TRPV1 in the modulation of tooth-movement pain. The expression levels of TRPV1 mRNA and protein were determined by real-time PCR and western blot, respectively. Moreover, pain levels were assessed using the rat grimace scale (RGS). The role of TRPV1 in modulating tooth-movement pain was examined by injecting a TRPV1 antagonist into the trigeminal ganglia of rats. A lentivirus containing a TRPV1 shRNA sequence was constructed and transduced into the rats' trigeminal ganglia. The results showed that the expression levels of TRPV1 protein and mRNA were elevated following tooth-movement pain. Pain levels increased rapidly on the 1 day, peaked on the 3 day and returned to baseline on the 14 day. The TRPV1 antagonist significantly reduced tooth-movement pain. The lentivirus containing a TRPV1 shRNA sequence was able to inhibit the expression of TRPV1 and relieved tooth-movement pain. In conclusion, TRPV1-based gene therapy may be a treatment strategy for the relief of orthodontic pain.
Animals ; Calcitonin Gene-Related Peptide ; Genetic Therapy ; Male ; Molar ; Pain ; Quality of Life ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; TRPV Cation Channels ; Tooth Movement Techniques ; Trigeminal Ganglion